Cargando…

Doravirine and Its Potential in the Treatment of HIV: An Evidence-Based Review of the Emerging Data

The utility of doravirine in the management of HIV-1 infection is approved for use in patients who are antiretroviral-naïve as well as patients who have achieved stable virologic suppression and are interested in replacing their current antiretroviral therapy. The role of doravirine continues to evo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rock, Alexander E, Lerner, Jeremy, Badowski, Melissa E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293906/ https://www.ncbi.nlm.nih.gov/pubmed/32606994 http://dx.doi.org/10.2147/HIV.S184018

Ejemplares similares

Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance
por: Rhee, Soo-Yon, et al.
Publicado: (2023)

Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate
por: Greaves, Wayne, et al.
Publicado: (2019)

Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV-1: What is the Hidden Potential of This Emerging Treatment?
por: Januszka, Jenna E, et al.
Publicado: (2023)

1011. Efficacy and Safety of Doravirine in Treatment-Naïve Adults ≥50 Years Old With HIV-1
por: Mills, Anthony, et al.
Publicado: (2020)

Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine
por: Molina, Jean-Michel, et al.
Publicado: (2022)

Real-life use of Doravirine in treatment-experienced people living with HIV: A multicenter Italian study
por: Mazzitelli, Maria, et al.
Publicado: (2022)

Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development
por: Martin, Elizabeth Anne, et al.
Publicado: (2020)

Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection
por: Pham, Hanh Thi, et al.
Publicado: (2020)

Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa
por: Steegen, Kim, et al.
Publicado: (2021)

Changes in weight and BMI with first-line doravirine-based therapy
por: Orkin, Chloe, et al.
Publicado: (2021)

Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen
por: Iannone, Valentina, et al.
Publicado: (2023)

Comparison of Efavirenz and Doravirine Developmental Toxicity in an Embryo Animal Model
por: Zizioli, Daniela, et al.
Publicado: (2023)

Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates
por: Asante-Appiah, Ernest, et al.
Publicado: (2021)

Evidence Regarding Rapid Initiation of Antiretroviral Therapy in Patients Living with HIV
por: Michienzi, Sarah M., et al.
Publicado: (2021)

545. Rational Design of Doravirine (DOR): A Review of Development From Bench to Patients
por: Hwang, Carey, et al.
Publicado: (2018)

Clinical utility of dronabinol in the treatment of weight loss associated with HIV and AIDS
por: Badowski, Melissa E, et al.
Publicado: (2016)

546. No Difference in MK-8591 and Doravirine Pharmacokinetics After Co-Administration
por: Matthews, Randolph, et al.
Publicado: (2018)

1009. Dolutegravir and Doravirine in Combination: When Standard Antiretroviral Regimens are Unacceptable
por: Denyer, Rachel, et al.
Publicado: (2020)

New Antiretroviral Treatment for HIV
por: Badowski, Melissa E., et al.
Publicado: (2016)

The DoDo experience: an alternative antiretroviral 2-drug regimen of doravirine and dolutegravir
por: Sammet, Stefanie, et al.
Publicado: (2023)

A Phase 1 Study to Evaluate the Drug Interaction Between Islatravir (MK-8591) and Doravirine in Adults Without HIV
por: Matthews, Randolph P., et al.
Publicado: (2021)

High Prevalence of Doravirine Resistance in HIV-1-Infected Patients with Virological Failure to an NNRTI-Based Single-Tablet Regimen
por: Tsai, Hung-Chin, et al.
Publicado: (2022)

Doravirine-associated resistance mutations in antiretroviral therapy naïve and experienced adults with HIV-1 subtype C infection in Botswana
por: Bareng, Ontlametse T., et al.
Publicado: (2022)

Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
por: Devred, Inès, et al.
Publicado: (2023)

Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1
por: Vaddady, Pavan, et al.
Publicado: (2020)

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate for Nonoccupational HIV-1 Postexposure Prophylaxis: A Prospective Open-Label Trial (DORAVIPEP)
por: Inciarte, Alexy, et al.
Publicado: (2023)

2548. Pharmacokinetic Analysis of Co-Administering Doravirine, Tenofovir Disoproxil Fumarate, Estradiol, and Spironolactone
por: Lam, Kevin, et al.
Publicado: (2023)

Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting
por: Maggi, Paolo, et al.
Publicado: (2023)

A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics
por: Badowski, Melissa E.
Publicado: (2017)

Telemedicine for HIV Care: Current Status and Future Prospects
por: Smith, Erica, et al.
Publicado: (2021)

Two’s a Company, Three’s a Crowd: A Review of Initiating or Switching to a Two-Drug Antiretroviral Regimen in Treatment-Naïve and Treatment-Experienced Patients Living with HIV-1
por: Badowski, Melissa, et al.
Publicado: (2020)

Vitamins, supplements and COVID-19: a review of currently available evidence
por: Speakman, Lauren L, et al.
Publicado: (2021)

Long-acting injectable antiretroviral therapy: will it change the future of HIV treatment?
por: Brizzi, Marisa, et al.
Publicado: (2023)

Prediction of Maternal and Fetal Doravirine Exposure by Integrating Physiologically Based Pharmacokinetic Modeling and Human Placenta Perfusion Experiments
por: Bukkems, V. E., et al.
Publicado: (2022)

Comparison of the Efficacy and Safety of a Doravirine-Based, Three-Drug Regimen in Treatment-Naïve HIV-1 Positive Adults: A Bayesian Network Meta-Analysis
por: Zhang, Ke, et al.
Publicado: (2022)

Doravirine/lamivudine/tenofovir disoproxil fumarate-induced hypertriglyceridemia in a newly diagnosed AIDS patient
por: Barchi, Virginia, et al.
Publicado: (2022)

HIV: how to manage low-level viraemia in people living with HIV
por: Hanners, Emily K, et al.
Publicado: (2022)

Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug–Drug Interactions
por: Khalilieh, Sauzanne, et al.
Publicado: (2020)

Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations
por: Wong, Alexander, et al.
Publicado: (2019)

Cryo-EM structures of wild-type and E138K/M184I mutant HIV-1 RT/DNA complexed with inhibitors doravirine and rilpivirine
por: Singh, Abhimanyu K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sg2chsr1c3qhjmco4sr3vn2pf8